Amsacrine (m-AMSA): A New Antineoplastic Agent Pharmacology, Clinical Activity and Toxicity
- 4 March 1985
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 5 (2) , 78-90
- https://doi.org/10.1002/j.1875-9114.1985.tb03406.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell broncliogenic carcinomaAmerican Journal of Clinical Oncology, 1983
- Meta AMSA (m‐AMSA) in Patients with Advanced Ovarian CarcinomaAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1982
- Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinomaEuropean Journal of Cancer and Clinical Oncology, 1982
- AMSA toxicity in patients with abnormal liver functionEuropean Journal of Cancer and Clinical Oncology, 1981
- On the mechanism of action of 4′-[(9-acridinyl)-amino] methanesulphon-m-anisididePublished by Elsevier ,1980
- Interaction of antitumor drugs with human erythrocyte ghost membranes and mastocytoma P815: A spin label studyBiochemical and Biophysical Research Communications, 1979
- BASE SPECIFICITY IN THE INHIBITION OF ONCORNAVIRUS REVERSE TRANSCRIPTASE AND CELLULAR NUCLEIC ACID POLYMERASES BY ANTITUMOR DRUGS *Annals of the New York Academy of Sciences, 1977
- Daunomycin-induced cardiotoxicity in children and adults: A review of 110 casesPublished by Elsevier ,1977
- DNA-binding characteristics of acridinylmethanesulphonanilide drugs: Comparison with antitumour propertiesPublished by Elsevier ,1976
- Potential antitumor agents. 12. 9-AnilinoacridinesJournal of Medicinal Chemistry, 1972